Automatized FACEmemory® scoring is related to Alzheimer’s disease phenotype and biomarkers in early-onset mild cognitive impairment: the BIOFACE cohort

Montserrat Alegret1,2*, Oscar Sotolongo-Grau1,2, Ester Esteban de Antonio1, Alba Pérez-Cordón1, Adelina Orellana1,2, Ana Espinosa1,2, Silvia Gil1,2, Daniel Jiménez1, Gemma Ortega1,2, Angela Sanabria1,2, Natalia Roberto1,2, Isabel Hernández1,2, Maitee Rosende-Roca1, Juan Pablo Tartari1, Emilio Alarcon-Martin1, Itziar de Rojas1,2, Laura Montreuil1, Xavier Morató1, Amanda Cano1, Dorene M. Rentz3,4, Lluís Tàrraga1,2, Agustín Ruiz1,2, Sergi Valero1,2, Marta Marquié1,2 and Mercè Boada1,2

Abstract

Background: FACEmemory® is the first computerized, self-administered verbal episodic memory test with voice recognition. It can be conducted under minimal supervision and contains an automatic scoring system to avoid administrator errors. Moreover, it is suitable for discriminating between cognitively healthy and amnestic mild cognitive impairment (MCI) individuals, and it is associated with Alzheimer’s disease (AD) cerebrospinal fluid (CSF) biomarkers. This study aimed to determine whether FACEmemory scoring is related to performance on classical memory tests and to AD biomarkers of brain magnetic resonance imaging (MRI) and CSF in patients with early-onset MCI (EOMCI).

Methods: Ninety-four patients with EOMCI from the BIOFACE study completed FACEmemory, classical memory tests (the Spanish version of the Word Free and Cued Selective Reminding Test -FCSRT-, the Word List from the Wechsler Memory Scale, third edition, and the Spanish version of the Rey–Osterrieth Complex Figure Test), and a brain MRI. Eighty-two individuals also underwent a lumbar puncture.

Results: FACEmemory scoring was moderately correlated with FCSRT scoring. With regard to neuroimaging MRI results, worse execution on FACEmemory was associated with lower cortical volume in the right prefrontal and inferior parietal areas, along with the left temporal and associative occipital areas. Moreover, the total FACEmemory score correlated with CSF AD biomarkers (Aβ1-42/Aβ1-40 ratio, p181-tau, and Aβ1-42/p181-tau ratio). When performance on FACEmemory was compared among the ATN classification groups, significant differences between the AD group and normal and SNAP groups were found.

Conclusions: FACEmemory is a promising tool for detecting memory deficits sensitive to early-onset AD, but it also allows the detection of memory-impaired cases due to other etiologies. Our findings suggest that FACEmemory scoring can detect the AD endophenotype and that it is also associated with AD-related changes in MRI and CSF in
**Background**

Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder causing dementia. It is characterized by a continuous decline in both cognitive and functional abilities along a spectrum from subjective cognitive decline to mild cognitive impairment (MCI) and dementia [1]. In only about 5% of cases do the first symptoms begin at less than 65 years of age, a condition known as early-onset Alzheimer’s disease (EOAD) [2].

The diagnosis of early-onset MCI (EOMCI) is more complicated, probably due to a lower suspicion of neurodegenerative conditions in younger people and a broad differential diagnosis [2]. This prodromal stage of dementia in these younger individuals is, in parallel, where cognitive deficits are already evident on formal neuropsychological testing although autonomy in their activities of daily living is preserved [3]. EOMCI is a distinct category of MCI not always related to prodromal AD, as many other underlying conditions, such as Parkinson’s disease or depression, can be associated with this entity [4]. Thus, there is a need for newer diagnostic tools to detect the first signs of AD in EOMCI.

It is well known that one of the endophenotypes proposed for AD is episodic memory disturbances [5]. Some studies report that EOAD patients have more difficulty learning new information that is not recalled with clues, reinforcing the hypothesis that a more severe storage or hippocampal memory impairment pattern exists in the younger group [6, 7]. However, other studies suggest that EOAD may begin with an atypical non-amnestic pattern [8, 9].

The International Working Group [10] recommends the use of the Free and Cued Selective Reminding Test (FCSRT) [11] to assess episodic memory. FCSRT is effective in detecting amnestic MCI and dementia [12], with total recall impairment being the core clinical phenotype of prodromal AD [13]. Moreover, FCSRT has been found to be useful in predicting conversion from MCI to AD dementia [14], and it is associated with AD neuroimaging [15] and cerebrospinal fluid (CSF) biomarkers [16]. However, this test requires a reliable and highly trained professional to administer it.

As a result of the growing interest in developing newer technological tools for detecting the first signs of AD prior to the MCI stage, we recently developed and validated the FACEmemory® test [17]. This is a computerized version of the abbreviated form [18] of the original Face-Name Associative Memory Exam (FNAME) [19], a complex episodic memory test developed by Dr. Rentz’s team [18] to detect preclinical [20] and prodromal AD. FACEmemory is unique in that it is the first self-administered verbal memory test with voice recognition and conducted under minimal supervision. It has an automatic scoring system to avoid administrator error. Moreover, it is suitable for discriminating between cognitively healthy and amnestic MCI (aMCI) individuals, who in most cases convert to AD [21, 22], and it is correlated with AD CSF biomarkers [17].

The work presented herein is part of the BIOFACE project, a longitudinal study based on a cohort of 97 patients with EOMCI and focused on increasing the knowledge of AD’s prodromal stages, including the clinical and biomarker characterization of EOMCI [23]. The main aim of the present study is to determine whether FACEmemory scoring is related to performance on classical memory tests and to AD biomarkers of brain magnetic resonance imaging (MRI) and CSF in patients with EOMCI. We hypothesized that worse performance on FACEmemory would be associated with worse performance on the FCSRT and would be related to MRI and CSF AD biomarkers in EOMCI.

**Methods**

**Participants**

A total of 97 participants with EOMCI from the BIOFACE study [23] were recruited at the Memory Unit of Ace Alzheimer Center Barcelona. Three were excluded from analysis because they failed to complete the FACEmemory test (one) or whole MRI data was not available for quantitative analysis (two).

**Neurobehavioral assessment**

As detailed previously [23], a comprehensive neuropsychological, neurological, and functional assessment at the Memory Unit of Ace Alzheimer Center Barcelona, as well as routine analyses of blood and structural brain neuroimaging, were administered to all BIOFACE participants within a time window of 3 months.

Within the diagnosis procedure of Ace Alzheimer Center Barcelona, all participants had a first neurological and neuropsychological visit (with the neuropsychological battery of Fundació ACE (NBACE) [24, 25]...
administered by one of the neuropsychologists of the team, including an accurate diagnosis to ensure that they fulfilled the BIOFACE inclusion criteria. The participants returned to the Memory Unit for an additional neuropsychological assessment, followed by the FACEmemory visit, which was performed in another office with a psychologist who invited each patient to sit at a table with a tablet and complete the FACEmemory test with minimal supervision (only technological issues were addressed). Finally, in the same week, each participant came back for an additional neuropsychological assessment administered by a neuropsychologist (A.P.) in the same order. Thus, the neuropsychological assessment included three visits: (1) the NBACE, (2) additional neuropsychological tests to detect prodromal AD, and (3) the FACEmemory test.

Inclusion criteria were diagnosis of MCI according to the Petersen [3] criteria (including the amnestic and non-amnestic types), a Clinical Dementia Rating of 0.5, age of onset under 65, Mini-Mental State Examination (MMSE) score ≥ 24, educational level of at least elementary school, capacity to provide written informed consent, and fluent Spanish language skills. Exclusion criteria were contraindication for brain MRI, presence of an underlying medical or neurological illness that could account for cognitive impairment based on lab tests or brain imaging, major psychiatric disorder, active drug abuse, and severe auditory/visual abnormalities.

In addition to FACEmemory, the following classical memory tests were administered: the Spanish version of the Word FCSRT [11, 26], the Word List from the Wechsler Memory Scale, third edition (WMS-III) [27], and the Spanish version of the Rey-Osterrieth Complex Figure Test (ROCF) [26].

**FACEmemory and other memory test procedures**

The FACEmemory test was administered via a tablet computer with voice recognition and a touchscreen, ensuring its standardized administration and immediate automatized scoring and registration of the results in an anonymous database.

As detailed elsewhere [17], the temporal sequence of FACEmemory was the following: two learning trials, a short-term memory task, and a long-term memory task that included face, name, and occupation memory recognition. The total test duration was approximately 30 min. Briefly, the first learning trial consisted of a total of 12 faces, each one associated with a name and an occupation that appeared beneath it for 8 s. The second learning trial followed the same procedure as the first one, but the 12 faces appeared in a different order. Participants were instructed to read the name and occupation appearing beneath each face aloud and to try to remember it. Then, the application asked the participants to press the red microphone button and say the name and occupation they remembered as being associated with each face. Two minutes after the second learning trial began, the application again asked the participants to say the name and occupation they remembered as being associated with each face. Finally, 20 min after the second learning trial, long-term memory assessment was initiated, which involved free recall and recognition tasks. First, the participants were instructed to recognize, from three faces, the face that had appeared in the first learning trial and to touch it. Then, the correct face appeared and the participants were asked to say the name and occupation they remembered for each face. After each answer, a screen appeared showing the correct face, and two rows below the face were three name options and three occupation options. The participants were instructed to touch the name and occupation they recognized as being associated with that face.

With regard to the Spanish version of the Word FCSRT [11], the task consists of learning 16 words that are presented on four pages. Participants were asked to read each word aloud and then say which of the words corresponded to a given semantic category. After this initial learning and encoding procedure, there were three recall trials, each preceded by a non-semantic interference task (countdown of 20 s). For each trial, participants were asked to remember as many words as possible, and then, the semantic category was provided for those items that were not recalled. The same recall procedure was repeated 20 min later.

The Word List from the WMS-III [27] was administered using a traditional procedure in which the list was presented orally in four consecutive learning trials, without using any interference list. After a 20-min delay, a free recall trial, followed by a yes/no recognition task, was administered [24].

With regard to the ROCF [26] test, a complex figure was placed in front of the participant, who was asked to copy it as accurately as possible. Then, the figure was removed from view. After a 20-min delay, the subject was asked to reproduce the figure from memory.

**Acquisition and processing of brain MRI images**

Scans were acquired in a Siemens MAGNETOM VIDA 3T scanner (Erlangen, Germany) using a 32-channel head coil from Clínica Corachán (Barcelona). T1-weighted images, for the morphological and the volumetric studies, were acquired using a gradient-echo 3D MPRAGE sequence with the following parameters: TR 2200 ms, TE 2.23 ms, TI 968 ms, 1.2-mm slice thickness, FOV 270 mm, and voxel measurement 1.1 × 1.1 × 1.2 mm. To complete the acquisition, a 3D isotropic FLAIR, an axial sequence T2-weighted and an axial sequence
Lumbar puncture and cerebrospinal fluid collection
This protocol followed the consensus recommendations established by the Alzheimer's Biomarkers Standardization Initiative [28]. Briefly, a lumbar puncture was performed by an experienced neurologist with the patients in a seated position and under fasting conditions. After applying local anesthesia (1% mepivacaine) subcutaneously, the neurologist obtained CSF by lumbar puncture in the intervertebral space of L3–L4. The fluid was collected passively in two 10-ml polypropylene tubes (Sarstedt Ref. 62610018). The first tube was analyzed externally for basic biochemistry (glucose, total proteins, proteinogram, and cell type and number). The second tube was centrifuged (2000×g 10 min at 4 °C), and the fluid was aliquoted into polypropylene tubes (Sarstedt Ref. 72694007) and stored at −80 °C until analysis. Time delay between CSF collection and storage was less than 2 h.

On the day of the analysis, the aliquots were thawed at room temperature and vortexed for 5–10 s to determine AD biomarkers in CSF. One aliquot/patient was used to determine the concentrations of Aβ1-42, Aβ1-40, t-tau, and p181-tau using chemiluminescence enzyme immunoassay (CLEIA) with the commercially available Lumipulse G™ reagents in the Lumipulse™ platform (Fujirebio, Europe) at the research laboratory of Ace Alzheimer Center Barcelona.

The ATN groups
Using CSF and MRI biomarkers, participants were classified into three categories according to the ATN scheme [29]. Those categories were normal AD biomarkers (A-T-N-), Alzheimer’s continuum (including A-T-N+, A+T+N+, A+T+N+, and A+T+N+), and non-AD pathologic changes (-SNAP-, including A-T+N-, A-T-N+ and A-T+N+), where A refers to aggregated Aβ, T to aggregated tau, and N to MRI neurodegeneration or neuronal injury. Cut-offs from the Fundació ACE biomarker research program (FACEBREP) cohort were used to dichotomize each CSF biomarker into +/- as follows: Aβ1-42/Aβ1-40 ratio< 0.063 for A, p181-tau> 54 pg/ml for T, and presence of neurodegeneration in the MRI for N.

The N classification was obtained using a machine learning method (Naive Bayes) [30]. As a training database, the subjects’ data were selected from the ADNI database (adni.loni.usc.edu) [31] as follows. Only baseline MRI data from individuals diagnosed with dementia and a cognitively healthy status at baseline were selected, for a total of 1222 data points. The volume from the hippocampus, entorhinal cortex, middle temporal cortex, and lateral ventricles, as well as the subject’s age and estimated intracranial volume, was chosen as independent variables. Subjects diagnosed with dementia were considered to be neurodegeneration positive (N+), while cognitively healthy subjects were considered as neurodegeneration negative (N−). To test the algorithm, ADNI data was randomly split in two datasets with 70% of the data as the training dataset and 30% as the test dataset. The algorithm so fed was tested and showed an accuracy of 82%, sensitivity of 82%, and specificity of 80% for N classification. So, the full ADNI dataset was used to build the prior probability function. Then, the values of independent variables for the BIOFACE cohort were calculated and the N values were assessed as the dichotomization of the posterior probability function.

Statistical analysis
Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS) version 26 for Windows (version 26.0; SPSS Inc., Chicago, IL). All data were examined for normality, skew, and restriction of range.

Descriptive analyses for demographical, neuropsychological, and clinical variables were performed. Pearson’s correlation analyses were carried out between FACE-memory scores/CSF AD biomarkers and age and schooling years. Moreover, t test and chi-square analyses were performed to compare demographical and FACE-memory scores between participants with and without a lumbar puncture or between men and women.

Univariate and multiple linear regression analyses (the stepwise procedure) were carried out to search for traditional memory variables (delayed free recall on the Word List from the WMS-III and Word FCSRT, total free recall/learning on the Word List from the WMS-III and...
on the Word FCSRT, and long-term visual recall on the ROCF) correlated with the total FACEmemory score, after adjusting for age, schooling years, and sex.

In the subsample with lumbar puncture, univariate linear regression analyses with FACEmemory and each CSF AD biomarker value, adjusting for age, schooling years, and sex, were carried out. Moreover, to search for differences between ATN groups (AD, SNAP, and normal), an analysis of covariance (ANCOVA) was performed.

For all the analyses, an effect was considered significant when \( p < 0.05 \) and all hypotheses were tested directionally at a 95% confidence level.

**Results**

**Demographic variables**

The whole sample consisted of 94 participants, including 37 men and 57 women. Their mean age was 60.74 (standard deviation (SD): 3.42) years, with a mean of 12.05 (SD: 5.08) schooling years. Their mean score on the MMSE was 28 (SD: 1.50), and on the FACEmemory, their mean score was 34.15 (SD: 18.92) points.

With regard to the type of MCI, 46 were amnestic and 48 were non-amnestic. Both groups did not significantly differ in age, sex, or years of formal education. However, as expected, aMCI performed significantly worse than non-amnestic mild cognitive impairment (naMCI) on the FACEmemory total score (mean: 26.87, SD: 16.56, and mean: 41.13, SD: 18.56, respectively; \( t = 3.92, p < 0.001 \)).

The subset of patients who underwent a lumbar puncture \((n = 82)\) and those who did not \((n = 12)\) were homogeneous on age \((t = 0.92, p = 0.357)\), sex \((\chi^2 = 1.19, p = 0.276)\), schooling years \((t = 0.22, p = 0.826)\), MMSE \((t = 0.00, p = 1.000)\), and total FACEmemory score \((t = 0.48, p = 0.629)\). With regard to the ATN groups, 24 subjects were classified as normal, 15 AD, and 43 non-AD/SNAP. Their demographic and clinical characteristics are detailed in Table 1.

The total FACEmemory score was found to be weakly correlated with age \((r = -0.22, p = 0.032)\), but not with schooling years \((r = 0.08, p = 0.419)\) or sex \((t = 0.16, p = 0.872)\).

**FACEmemory vs traditional episodic memory tests**

The performance on the memory tests administered is detailed in Table 2. Convergent validity of FACEmemory was determined based on performance on the FCSRT. Univariate linear regression analyses showed FACEmemory to be significantly associated with each individual traditional memory test (as detailed in Table 3). In a multiple linear regression analysis using classical memory tests as independent variables, adjusted by age, schooling, and sex, long-term free recall on the Word List from the WMS-III and on the FCSRT emerged as the only significant factors associated with the total FACEmemory score \((F = 12.830, p < 0.001; \text{beta} = 0.42, p < 0.001 \text{ and beta} = 0.30, p = 0.001, \text{respectively})\).

**FACEmemory vs cortical volume measured by brain MRI**

The SBM analysis showed the presence of four different clusters where there was a significant correlation between cortical volume and the FACEmemory total score. In the left hemisphere, there were two clusters: the first one comprised the fusiform gyrus and associative visual cortex \((p < 0.0002)\), and the second one was centered in the middle temporal cortex \((p < 0.01)\). The other two clusters were located in the right prefrontal cortex \((p < 0.0008)\) and in the parietal angular and supramarginal gyri \((p < 0.004)\).

For all clusters, there was a positive correlation between memory performance and cortical volume; that is, worse performance on the FACEmemory test was associated with lower cortical volume in those areas. All the clusters are described in Table 4 and shown in Fig. 1.

---

**Table 1** Demographic and clinical characteristics of the whole sample and ATN groups

|                     | Whole sample | ATN groups |
|---------------------|-------------|------------|
|                     |             | Normal     | AD        | SNAP      |
| N                   | 94          | 24         | 15        | 43        |
| Sex n (%) men       | 37 (39.36)  | 11 (45.80) | 5 (33.30) | 18 (41.90) |
| Age in years (mean/SD) | 60.74 (3.42) | 59.83 (2.55) | 59.83 (2.55) | 60.30 (4.17) |
| Schooling years (mean/SD) | 12.05 (5.08) | 12.42 (5.49) | 12.42 (5.49) | 11.86 (4.39) |
| MMSE (mean/SD)      | 28.00 (1.50) | 28.13 (1.57) | 27.80 (1.61) | 28.00 (1.50) |
| MCI type n (%) aMCI | 46 (48.94)  | 7 (29.16)  | 9 (60.00) | 21 (48.84) |

ATN groups: (1) Normal: normal AD biomarkers (A-T-N-); (2) AD: Alzheimer’s disease continuum (including A+T-N-, A+T+N-, A+T+N+); and (3) SNAP: non-AD pathologic changes (including A-T-N-, A+T-N+, and A+T+N+), where A refers to aggregated Aβ, T to aggregated tau, and N to MRI neurodegeneration or neuronal injury.

MMSE Mini-Mental State Examination, SD Standard deviation, MCI Mild cognitive impairment, aMCI Amnestic mild cognitive impairment.
In the subsample of 82 patients who underwent lumbar puncture, a correlation analysis among demographical variables (age, sex, and education) showed significant associations between age and the Aβ1-42/Aβ1-40 ratio ($r = −0.35, p = 0.001$), p181-tau ($r = 0.32, p = 0.003$), and the Aβ1-42/p181-tau ratio ($r = 0.39, p = 0.009$) levels, but not with Aβ1-42 alone ($r = 0.04, p = 0.728$). Sex and schooling years were not significantly associated with any CSF variable. Univariate linear regression analyses with FACEmemory and each CSF variable, covaried by age, schooling years, and sex, showed that the total FACEmemory score was moderately correlated with the CSF Aβ1-42/Aβ1-40 ratio, p181-tau, and the Aβ1-42/p181-tau ratio, but only weakly with Aβ1-42 levels (see Table 5 for details).

**FACEmemory vs ATN groups**

With regard to ATN analysis, when comparing the total FACEmemory score among normal, AD, and non-AD/SNAP groups, a statistically significant effect was found among groups ($F = 9.018, p < 0.001$). Post hoc analysis showed that the AD group differed significantly from the normal and SNAP groups (with a mean difference of 23.90 (SE: 5.64), $p < 0.001$, and 15.73 (SE: 5.14), $p = 0.009$, respectively) (for details see Table 2).

**Table 2** Performance on FACEmemory and the other memory tests

| Test/variable | Whole sample | ATN groups | $F (1, 79)$ | $P$ |
|---------------|--------------|------------|------------|-----|
|               |              | Normal     | AD         | SNAP |
| FACEmemory    |              |            |            |      |
| LN1+2         | 3.78 (4.17)  | 5.71 (4.71)* | 1.80 (2.34) | 3.48 (3.53) | 5.381 | 0.006 |
| LO1+2         | 11.88 (5.58) | 13.67 (4.49)* | 7.60 (6.74) | 12.58 (5.03)* | 6.803 | 0.002 |
| RSN           | 2.62 (2.88)  | 4.00 (3.18)* | 1.20 (1.78) | 2.47 (2.55)* | 5.515 | 0.006 |
| RSO           | 7.15 (3.18)  | 8.42 (2.19)* | 4.27 (4.04) | 7.58 (2.78)* | 10.173 | <0.001 |
| FR            | 11.91 (0.35) | 12.00 (0.00) | 11.60 (0.74) | 11.95 (0.21)* | 7.115 | 0.001 |
| RLN           | 2.23 (2.62)  | 3.29 (2.87)* | 0.73 (0.96) | 2.28 (2.45)* | 5.252 | 0.007 |
| RLO           | 6.50 (3.39)  | 8.13 (2.67)* | 3.67 (3.50) | 6.60 (3.27)* | 9.257 | <0.001 |
| REN           | 8.00 (2.71)  | 8.88 (2.07) | 7.27 (2.74) | 7.74 (2.91) | 2.064 | 0.134 |
| REO           | 11.05 (1.53) | 11.63 (0.87)* | 10.00 (2.00) | 11.23 (1.23)* | 7.331 | 0.001 |
| Total score   | 34.15 (18.92) | 43.17 (16.96)* | 19.27 (17.84) | 35.00 (16.98)* | 9.018 | <0.001 |

| Word FCSRT    |              |            |            |      |
|               |              |            |            |      |
| Total free recall | 22.95 (6.47) | 24.17 (5.81)* | 18.07 (7.38) | 23.98 (5.91)* | 5.764 | 0.005 |
| Total recall   | 38.44 (8.57) | 40.50 (5.39)* | 31.60 (13.29) | 39.74 (7.10)* | 6.586 | 0.002 |
| Delayed free recall | 8.05 (4.93) | 8.46 (2.80)* | 4.80 (4.71) | 9.05 (5.78)* | 4.278 | 0.017 |
| Delayed total recall | 12.75 (3.54) | 13.92 (1.86)* | 8.40 (5.38) | 13.70 (2.12)* | 20.788 | <0.001 |

| ROCFT         |              |            |            |      |
|               |              |            |            |      |
| Total recall   | 12.36 (5.56) | 14.44 (4.58)* | 8.47 (6.33) | 12.67 (5.26)* | 5.995 | 0.004 |

| Word list from the WMS-III | | | |
|-----------------------------|----------------|----------------|----------------|--------------|
| Delayed free recall | 4.95 (2.51) | 5.58 (2.19)* | 3.27 (2.63) | 5.48 (2.40)* | 5.452 | 0.006 |
| Recognition memory | 20.82 (3.54) | 21.46 (2.95) | 19.47 (4.37) | 20.95 (3.57) | 1.494 | 0.231 |

| β | $F (1, 91)$ | $P$ |
|---|------------|-----|
| Total free recall | 0.44 | 21.515 | <0.001 |
| Total recall | 0.37 | 14.668 | <0.001 |
| Delayed free recall | 0.48 | 26.940 | <0.001 |
| Delayed total recall | 0.42 | 19.597 | <0.001 |

| ROCFT |          |            |            |      |
|-------|----------|------------|------------|-----|
| Delayed recall | 0.45 | 23.454 | <0.001 |

| Word list from the WMS-III | | | |
|-----------------------------|----------------|----------------|----------------|--------------|
| Delayed free recall | 0.55 | 40.591 | <0.001 |
| Recognition memory | 0.38 | 15.819 | <0.001 |

In the subsample of 82 patients who underwent lumbar puncture, a correlation analysis among demographical variables (age, sex, and education) showed significant associations between age and the Aβ1-42/Aβ1-40 ratio ($r = −0.35, p = 0.001$), p181-tau ($r = 0.32, p = 0.003$), and the Aβ1-42/p181-tau ratio ($r = 0.39, p = 0.009$) levels, but not with Aβ1-42 alone ($r = 0.04, p = 0.728$). Sex and schooling years were not significantly associated with any CSF variable. Univariate linear regression analyses with FACEmemory and each CSF variable, covaried by age, schooling years, and sex, showed that the total FACEmemory score was moderately correlated with the CSF Aβ1-42/Aβ1-40 ratio, p181-tau, and the Aβ1-42/p181-tau ratio, but only weakly with Aβ1-42 levels (see Table 5 for details).
Discussion

In a cohort of patients with EOMCI, the results of the present study show that the worse performance on the FACEmemory test was related to worse performance on traditional episodic memory tests sensitive to the AD endophenotype and was also associated with AD-related neuroimaging and CSF biomarkers. This is the first study demonstrating the convergent validity of a computerized

Table 4 Cluster characteristics for SBM analysis with cortical volume and total FACEmemory score

| Hemisphere | Cortical areas affected                              | Size (mm²) | Cluster wise p value | Brodmann areas affected                                      | CoG Talairach coordinates (X, Y, Z) |
|------------|------------------------------------------------------|------------|----------------------|----------------------------------------------------------------|-------------------------------------|
| Left       | Fusiform, lateral occipital                         | 745        | 0.0002               | Associative visual cortex (19), Fusiform gyrus (37)            | −31, −79, −11                       |
| Left       | Middle temporal, bank of superior temporal sulcus   | 316        | 0.01                 | Superior temporal gyrus (22)                                   | −62, −42, −7                        |
| Right      | Superior frontal, rostral middle frontal            | 483        | 0.0008               | Dorsolateral prefrontal cortex (9), anterior prefrontal cortex (10) | 10, 59, 27                          |
| Right      | Inferior parietal                                   | 426        | 0.004                | Angular gyrus (39), Supramarginal gyrus (40)                   | 46, −50, 24                        |

Fig. 1 Clusters of association on left (a, b) and right (c, d) hemispheres between total FACEmemory score and cortical volume. The color map represents the value of log probabilities in the association. A worse performance on FACEmemory is associated with a lower cortical volume on each cluster.

Table 5 Univariate linear regression analyses with FACEmemory and each individual CSF variable

|          | β        | F (1, 80) | P value |
|----------|----------|-----------|---------|
| Aβ1-42   | −0.24    | 5.011     | <0.028  |
| p181-tau | −0.44    | 19.454    | <0.001  |
| Aβ1-42/Aβ1-40 ratio | 0.41 | 16.538 | <0.001 |
| Aβ1-42/p181-tau ratio | 0.37 | 12.473 | 0.001 |
verbal episodic memory tool with voice recognition, the FACEmemory test, and its correlation with MRI and CSF variables [29, 32, 33].

Firstly, as expected, patients with a diagnosis of aMCI performed significantly worse on the FACEmemory test than those with naMCI. With regard to the association between FACEmemory and classical memory test performances, univariate linear regression analyses showed worse performance on the computerized FACEmemory test significantly associated with visual and verbal long-term memory on classical memory tests (Word FCSRT, ROCFT, and Word List from the WMS-III). However, a multiple linear regression analysis showed that it was mainly related to worse performance on delayed free recall on the FCSRT and the Word List from the WMS-III, demonstrating that FACEmemory allows the detection of the AD endophenotype or storage impairments in episodic memory, the most important risk factor for conversion from MCI to AD dementia [21, 22, 34, 35]. The FCSRT is another memory test that enhances learning and can distinguish retrieval from storage impairment [11, 36]. Thus, our findings support that FACEmemory is sensitive to storage or hippocampal memory dysfunction [13, 37], reinforcing that it may be a suitable endophenotype of AD [5].

Cognitive approaches conceptualizing face-name associative memory have demonstrated that associating unfamiliar faces with proper names is a more complex task than other episodic memory tests because it is an arbitrary association [38]. The FACEmemory test asks the participants to learn the name and occupation of 12 unknown faces, demanding arbitrary face-name associations, which are sensitive to preclinical and prodromal AD [20, 39]. Thus, consistent with previous studies with different versions of FNAME [20, 39, 40], FACEmemory may be a suitable test to detect episodic memory impairment, which is needed for the early detection of AD [21, 22, 41].

With regard to neuroimaging MRI results, the present study found that worse execution on FACEmemory was associated with lower cortical volume in associative visual, prefrontal, and temporo-parietal areas. These brain regions are sensitive to EOAD. It is well known that medial temporal, prefrontal, parietal, and occipital cortices are significantly involved in EOAD pathology [8, 42–45], with a predominant posterior neocortical atrophy when compared to late-onset AD [8, 46]. Moreover, this finding agrees with previously published neuroimaging studies demonstrating that faces are encoded by the non-dominant (usually right) hemisphere and names and occupations are encoded by the language areas of the brain, the dominant (usually left) hemisphere [47]. To learn and recall the names and occupations of unknown faces implicates bilateral associative occipito-temporal cerebral regions with extensive connections to cortical areas, which is the specific neural function disrupted in AD [20, 47]. For this reason, FACEmemory performance requires cognitive functions highly vulnerable to AD.

Finally, worse execution on FACEmemory was found to be moderately associated with the Aβ1-42/Aβ1-40 ratio, p181-tau, and the Aβ1-42/p181-tau ratio and weakly with Aβ1-42 levels. It is well known that the Aβ1-42/Aβ1-40 ratio is more sensitive than Aβ1-42 alone to detect AD pathology, and its use is recommended when analyzing CSF AD biomarkers to improve the percentage of appropriately diagnosed MCI patients [48–50]. Consequently, the correlation found in this study with the FACEmemory test is of great value because it could reflect sensitive AD pathological changes in CSF. These results reinforce studies demonstrating an association between amyloid burden, either with PET imaging or CSF, and performances on traditional (the original FNAME [20], the Spanish version of FNAME [39]) and computerized (PAL CANTAB [5], FACEmemory [17]) episodic memory tests. FACEmemory scoring was also found to be related to p181-tau and the Aβ1-42/p181-tau ratio, supporting the idea that biomarkers of neurodegeneration are closely related to clinical symptoms [29], taking into account that the Aβ1-42/p181-tau ratio includes both AD biomarkers.

With regard to ATN classification [29], when performance on FACEmemory® was compared between 24 EOMCI subjects with normal AD biomarkers (A-T-N-), 43 SNAP (including A-T+N-, A-T+N+, and A-T+N+), and 15 AD continuum (A+T+N-, A+T+N+, A+T+N+, and A+T+N+), a significant effect was found among groups. A mean difference of 23.9 points in the FACEmemory score was detected between normal and AD ATN groups. These findings support that this test seems to be a diagnostic tool that reflects AD pathological changes [29, 51]. Moreover, the AD ATN group had the highest percentage of patients with aMCI and performed considerably lower on most of the memory tests compared to the other ATN groups. However, the normal and SNAP ATN groups also included memory-impaired cases (29.16% and 48.74%, respectively). Although the original FNAME was created to detect preclinical AD [20], the results of the present study suggest that FACEmemory will also allow the detection of memory-impaired cases with other etiologies. In fact, EOMCI is not always related to prodromal AD, as many other underlying conditions (i.e., neurodegenerative, psychiatric) can be associated with this MCI category [4].

In our opinion, the findings of the present study are important because they pave the way for a novel automatized method to detect AD and non-AD MCI in younger people. Consequently, FACEmemory may be
a suitable complex episodic memory test to be used in remote settings, such as in the context of clinical trials, in a standardized and easy way. Moreover, the complexity of FACEmemory makes it a potential complement to classical memory testing in clinical practice of patients with very early cognitive impairment.

Further longitudinal studies will be needed to determine whether lower baseline scores on FACEmemory are related to an increased risk of developing AD or another type of dementia.

Limitations

We acknowledge that our study has several limitations. First, the study design is cross-sectional. However, this is the first step of the BIOFACE project, in which all participants are being followed up annually with clinical and biomarker assessments. Secondly, not all recruited participants gave their consent for a CSF sample, but we recognize that some of them were reluctant to undergo a lumbar puncture due to it being an invasive, not completely innocuous process that can cause pain or discomfort to the patient. Thirdly, ADNI data was used as a training dataset for the neurodegeneration classification algorithm. ADNI data contains subjects with a wider age range which are older, on average, than the current dataset. Although the machine learning algorithm chose the proper prior distribution for any involved variable, it automatically discarded a considerable number of subjects from the training database. The use of a fully representative dataset for the current sample could be worthy of study. Finally, although all participants have been accurately characterized with an exhaustive cognitive neuropsychological assessment and multimodal AD biomarkers, the small sample size may prevent us from making robust conclusions. However, it should be noted that this is a single-center study and patients with an early-onset cognitive impairment are less frequently derived to a memory clinic than those with late-onset cognitive impairment.

Conclusion

The results of this study confirm that FACEmemory is a promising tool for detecting memory deficits related to underlying AD, but also for detecting memory-impaired cases with other etiologies. Our findings suggest that FACEmemory scoring can detect the endophenotype of AD, which is a hippocampal memory impairment. It is also associated with AD-related changes in MRI and CSF in patients with EOMCI, an MCI subtype in which a diagnosis of prodromal AD usually takes longer, probably due to a lower suspicion of a neurodegenerative condition in younger people. However, FACEmemory can also detect memory-impaired cases with a non-AD etiology. The computerized FACEmemory tool might be an opportunity for facilitating early detection of memory impairment in younger people than 65, who have a growing interest in new technologies.

Abbreviations

AD: Alzheimer’s disease; aMCI: Amnestic mild cognitive impairment; ANCOVA: Analysis of covariance; CSF: Cerebrospinal fluid; EOAD: Early-onset Alzheimer’s disease; EOMCI: Early-onset mild cognitive impairment; FACEBREP: Fundació ACE biomarker research program; FCGRIT: Free and Cued Selective Reminding test; FNAME: Face-Name Associative Memory Exam; FR: Face recognition; LN+2: Names recalled in learning 1 + 2; LO1+2: Occupations recalled in learning 1 + 2; MCI: Mild cognitive impairment; MRI: Magnetic resonance imaging.; MMSE: Mini-Mental State Examination; N+4: Neurodegeneration positive; N−: Neurodegeneration negative; naMCI: Non-amnestic mild cognitive impairment; NIBACE: Neuropsychological battery of Fundació ACE; REN: Names recognized; ROCF: Rey-Osterrieth Complex Figure Test; RSN: Names in short recall; SBM: Surface-based morphometry; SD: Standard deviation; SNAP: Non-AD pathologic changes; SPSS: Statistical Package for the Social Sciences; WMS-III: Wechsler Memory Scale, third edition.

Acknowledgements

We acknowledge all individuals who participated in the BIOFACE project; without their collaboration, this work would not have been possible. Ace Alzheimer Center Barcelona is a member of the Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades. We also want to thank Raul Espinosa for his inspiration, support, and persistence in finding a way to automate the tool; Xavier Mantruba, Tanya Valero, and Gemma Boada from Editorial Glosa; Mercedes Pageo from IECSA; Pau Plana from 3&Point Solutions Informátiques; and all the participating investigators and personnel from Ace Alzheimer Center Barcelona for their close collaboration and continuous intellectual input.

Authors’ contributions

Conceptualization and design of the study: MA, OS, MB, SG, MM, EM, SV, DMR, AR, and LT. Analysis and interpretation of the data: MA, OS, AO, SB, MB, XM, EA, IR, AR, MM, MB, and DMR. Analysis of the CSF biomarkers: AO, LM, AR, and AC. Analysis of the MRI: OS. Enrollment and assessment of patients in the Fundació ACE: MA, DJ, EE, SG, MM, MR, JP, JR, NR, CR, AS, AP, AE, GO, and MR. Critical review and continuous intellectual input.

Funding

This work was funded by the research funds of the Ace Alzheimer Center Barcelona. The BIOFACE study has been funded by the Instituto de Salud Carlos III (ISCIII) Acción Estratégica en Salud, integrated in the Spanish National RDCI Plan and financed by ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER) grant PI17/01474 awarded to MB and SG (principal investigators), and AO, OS, MA, AE, AP, and LM (coinvestigators). None of the authors received financial support for the present manuscript. However, with regard to grants and fees from any entity during the past 3 years, Itziar de Rojas was supported by a national grant from the Instituto de Salud Carlos III F120/00215; Amanda Cano received the grant Juan de la Cierva (F12018-036012-I) from the Spanish Ministry of Science, Innovation and Universities; Marta Marquié received funding from the Instituto de Salud Carlos III (ISCIII) Acción Estratégica en Salud, integrated in the Spanish National RDCI Plan and financed by ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER) grant PI19/00335; Dorene Rentz received the NIA SU2ZCA609426-03; Mobile Toolbox for Monitoring Cognitive Function SP30AG062421-02: Outreach Recruitment and Engagement Core 2P01AG036694-11-Harvard Aging Brain Study and received consulting fees from Neurotrack and Biogen Idec, payment for the IMPACT AD course and financial support for attending ACTC, and AAIC meetings; Agustín Ruiz received support from the Innovative Medicines Initiative 2 Joint Undertaking
which receives support from the European Union’s Horizon 2020 research and innovation programme (ADAPTED Grant No. 115975; Instituto de Salud Carlos III (ISCIII) grants PI13/02434, PI16/01861, and PI19/01301; and Acción Estratégica en Salud, integrada en el Programa Nacional R+D+I Plan and funded by ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER) and IFC-3nuD-2 "Multinational research projects on Personalised Medicine for Neurodegenerative Diseases" PREADAPT project. Grant no. AC19/00097, CIBERNED 2019/08, GRIFOLSA SA and Fundación Bancaria La Caixa for the GR@ACE/DEGESCO research program.

Availability of data and materials
Data used can be requested through the corresponding author.

Declarations

Ethics approval and consent to participate
The BIOFACE study was approved by the Ethics Committee of Hospital Clinic (Barcelona, Spain). Prior to the evaluation, written informed consent was obtained from all participants. The study was conducted in accordance with the Declaration of Helsinki and with Spanish biomedical laws (Law 14/2007, July 3, about biomedical research; Royal Decree 1716/2011, November 18).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Ace Alzheimer Center Barcelona—Universitat Internacional de Catalunya, Gran Via de Carles III, 85 bis, 08028 Barcelona, Spain. 2 Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain. 3 Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women’s Hospital, Boston, MA, USA. 4 Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.

Received: 9 December 2021 Accepted: 10 March 2022
Published online: 18 March 2022

References
1. Dubois B, Feldman HH, Jacova C, Cummings JL, DeKosky ST, Barberger-Gateau P, et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol. 2010;9:1118–27.
2. Tábuas-Pereira M, Baldeiras I, Duro D, Santiago B, Ribeiro MH, Leitão MJ, et al. Prognosis of mild cognitive impairment: comparison of conversion rates and its predictors. Geriatrics. 2016;1:1–12.
3. Petersen RC. MILD cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183–94.
4. Apostolova LG, Aisen P, Eloyan A, Fagan A, Fargo KN, Foroud T, et al. The differentiated clinical presentation of early and late-onset Alzheimer’s disease. Brain. 2007;130:720–30.
5. Petersen PR, Ganguli M, Krishnan S, et al. A reduced neuropsychological battery for the early detection of Alzheimer’s disease. Arch Neurol. 2001;58:349–54.
6. DeCarli C, Frisoni GB, Clark CM, Harvey D, Grundman M, Petersen RC, et al. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol. 2007;64:108–15.
7. Frisoni GB, Pievani M, Tosta C, Sabattoli F, Bresciani L, Bonetti M, et al. The topography of grey matter involvement in early and late onset Alzheimer’s disease. Brain. 2007;130:720–30.
8. Mendez MF. Early-onset Alzheimer disease and its variants. Continuum (Minneap Minn). 2019;25:54–51.
9. Palau A, Gutiérrez-Iglesias B, Alegría M, Pujadas F, Olabarrieta M, Llebaria D, et al. Differentiated clinical presentation of early and late-onset Alzheimer’s disease: is 65 years of age providing a reliable threshold? J Neurol. 2015;262:1238–46.
10. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614–29.
11. Grober E, Buschke H, Katzey SR. Genuine memory deficits in dementia. Dev Neuropsychol. 1987;3:13–36.
12. Grober E, Wakefield D, Ehrlich AR, Mabie P, Lipton RB. Identifying memory impairment and early dementia in primary care. Alzheimers Dement Diagnosis Assess Dis Monit. 2017;6:188–95.
13. Dubois B, Burn D, Goetz C, Larson D, Brown RG, Broe GA, et al. Diagnostic procedures for Parkinson’s disease dementia: recommendations from the Movement Disorder Society Task Force. Mov Disord. 2007;22:2314–24.
14. Grober E, Lipton RB, Hall C, Crystal H. Memory impairment on free and cued selective reminding predicts dementia. Neurology. 2000;54:827–32.
15. Philippi N, Noblet V, Duron E, Cretin B, Bouly C, Wisniewski I, et al. Exploring anterograde memory: a volumetric MRI study in patients with mild cognitive impairment. Alzheimers Res Ther. 2016;8:1–14.
16. Xie J, Gabelle A, Dorey A, Garnier-Crussard A, Perret-Liaudet A, et al. Initial memory deficit profiles in patients with a cerebrospinal fluid Alzheimer’s disease signature. J Alzheimers Dis. 2014;41:1099–106.
17. Alegría M, Muñoz N, Roberto N, Rentz DM, Valero S, Gil S, et al. A computerized version of the Short Form of the Face-Name Associative Memory Exam (FACEmemory®) for the early detection of Alzheimer’s disease. Alzheimers Res Ther. 2020;12:1–11.
18. Papp KV, Amariglio RE, Dekhtyar M, Roy K, Wigman S, Bamfo R, et al. Development of a psychometrically equivalent short form of the face-name associative memory exam for use along the early alzheimers disease trajectory. Clin Neuropsychol. 2014;28:771–85.
19. Amariglio RE, Friske K, Olson LE, Wadsworth LP, Lorius N, Sperling RA, et al. Validation of the face name associative memory exam in cognitively normal older individuals. J Clin Exp Neuropsychol. 2012;34:580–7.
20. Rentz DM, Amariglio RE, Becker JA, Frey M, Olson LE, Friske K, et al. Face-name associative memory performance is related to amyloid burden in normal elderly. Neuropsychologia. 2011;49:2776–83.
21. Espinosa A, Alegría M, Valero S, Vinyes-Junquè G, Hernández I, Mauleón A, et al. A longitudinal follow-up of 550 mild cognitive impairment patients: evidence for large conversion to dementia rates and detection of major risk factors involved. J Alzheimers Dis. 2013;34:769–80.
22. Otlla-Cucarella J, Ferri-Cascales R, Alegría M, Gasparrini R, Díaz-Ortiz LM, Ríos R, et al. Risk of progression to Alzheimer’s disease for different neuropsychological mild cognitive impairment subtypes: a hierarchical meta-analysis of longitudinal studies. Psychol Aging. 2018;33:1007–21.
23. Esteban de Antonio E, Perez-Cordon A, Gil S, Orellana A, Cano A, Alegría M, et al. BIOSPACE: a prospective study of risk factors, biomarkers and cognition in a cohort of individuals with early-onset mild cognitive impairment. Study rationale and research protocols. J Alzheimers Dis. 2021;83:1233–49.
24. Alegría M, Espinosa A, Vinyes-Junquè G, Valero S, Hernández I, Tárraga L, et al. Normative data of a brief neuropsychological battery for Spanish individuals older than 49. J Clin Exp Neuropsychol. 2012;34:209–19.
25. Alegría M, Espinosa A, Valero S, Vinyes-Junquè G, Ruiz A, Hernández I, et al. Cut-off Scores of a Brief Neuropsychological Battery (NBACE) for Spanish individual adults older than 44 years old. PLoS One. 2013;8:1–8.
26. Peña-Casanova J, Gramunt-Fombuena N, Quiñones-Úbeda S, Sánchez-Benavides G, Aguilar M, Badenes D, et al. Spanish Multicenter Normative Studies (NEURONORMA project): norms for the Rey-Osterrieth complex figure (copy and memory), and free and cued selective reminding test. Arch Clin Neuropsychol. 2009;24:371–93.
27. Wechsler D. WMS-III. Wechsler Memory Scale—Third Edition. Administration and scoring manual. San Antonio: The Psychological Corporation; 1997.
28. Vanderstichele H, Bbb M, Englebohrs S, Le Bastard N, Lewczuk P, Molinuevo JL, et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer’s disease diagnosis: a consensus paper from the Alzheimer’s Biomarkers Standardization Initiative. Alzheimers Dement. 2012;8:65–73.
29. Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Budd Haerberlein S, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s Disease. Alzheimers Dement. 2018;14:535–62.
30. Domingos P, Pazzani M. On the optimality of the simple Bayesian classifier under zero-one loss. Mach Learn. 1997;29:103–30.
31. The ADNI team. ADNIMERGE: Alzheimer’s disease neuroimaging initiative. R package version 0.0.1. 2021.
32. Fleisher AS, Sun S, Taylor C, Ward CP, Gamst AC, Petersen RC, et al. Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology. 2008;70:191–9.
33. Han SD, Gruhl J, Beckert L, Dodge HH, Stricker NH, Farias S, et al. Beta amyloid, tau, neuroimaging, and cognition: sequence modeling of biomarkers for Alzheimer’s disease. Brain Imaging Behav. 2012;6:910–20.
34. Alegret M, Cabezas-Borrós G, Vinyes-Junquè G, Espinosa A, Valero S, Hernández I, et al. A two-year follow-up of cognitive deficits and brain perfusion in mild cognitive impairment and mild Alzheimer’s disease. J Alzheimers Dis. 2012;30:109–20.
35. Espinosa A, Alegret M, Pesini P, Valero S, Laffuente A, Buendía M, et al. Cognitive composites domain scores related to neuroimaging biomarkers within probable-amnestic mild cognitive impairment-storage subtype. J Alzheimers Dis. 2017;57:447–59.
36. Grober E, Veroff AE, Lipton RB. Temporal unfolding of declining episodic memory on the Free and Cued Selective Reminding Test in the pre-dementia phase of Alzheimer’s disease: implications for clinical trials. Alzheimers Dement Diagnosis Assess Dis Monit. 2018;10:161–71.
37. Chen KHM, Chuah LYM, Sim SKY, Chee MWL. Hippocampal region-specific contributions to memory performance in normal elderly. Brain Cogn. 2010;72:400–7.
38. Werheid K, Clare L. Are faces special in Alzheimer’s disease? Cognitive conceptualisation, neural correlates, and diagnostic relevance of impaired memory for faces and names. Cortex. 2007;43:898–906.
39. Sanabria A, Alegret M, Rodríguez-Gómez O, Valero S, Sotolongo-Grau O, Monté-Rubio G, et al. The Spanish version of Face-Name Associative Memory Exam (S-FNAME) performance is related to amyloid burden in subjective cognitive decline. Sci Rep. 2018;8:1–9.
40. Alegret M, Valero S, Ortega G, Espinosa A, Sanabria A, Hernández I, et al. Validation of the Spanish version of the face name associative memory exam (S-FNAME) in cognitively normal older individuals. Arch Clin Neuropsychol. 2015;30:712–20.
41. Bondi MW, Edmonds EC, Jak AJ, Clark LR, Delano-Wood L, McDonald CR, et al. Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. J Alzheimers Dis. 2014;42:275–89.
42. Möller C, Vrenken H, Jiskoot L, Versteeg A, Barkhof F, Scheltens P, et al. Different patterns of gray matter atrophy in early- and late-onset Alzheimer’s disease. Neurobiol Aging. 2013;34:2014–22.
43. Reitz C, Rogaeva E, Beecham GW. Late-onset vs nonmendelian early-onset Alzheimer disease: a distinction without a difference? Neuron Genet. 2020;6:e512.
44. Mendez MF, Lee AS, Joshi A, Shapira JS. Nonamnestic presentations of early-onset Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2012;27:413–20.
45. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, et al. Molecular, structural, and functional characterization of Alzheimer’s disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709–17.
46. Mendez MF. Early-onset Alzheimer’s disease: nonamnestic subtypes and type 2 AD. Arch Med Res. 2012;43:677–85.
47. Mangels JA, Manzi A, Summerfield C. The first does the work, but the third time’s the charm: the effects of massed repetition on episodic encoding of multimodal face–name associations. J Cogn Neurosci. 2009;22:457–73.
48. Janelidze S, Zetterberg H, Mattsson N, Palmqvist S, Vanderstichele H, Lindberg O, et al. CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol. 2016;3:154–65.
49. Hansson O, Lefharn S, Otto M, Zetterberg H, Lewczuk P. Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s disease. Alzheimers Res Ther. 2019;11:34.
50. Baldeiras I, Santana I, Leitão MJ, Gens H, Pascoal R, Tábuas-Pereira M, et al. Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer’s disease dementia in mild cognitive impairment. Alzheimers Res Ther. 2018;10:1–15.
51. Pérez-Grijalva V, Arbizu J, Romero J, Prieto E, Pesini P, Sarasa L, et al. Plasma Aβ42/Aβ40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 study. Alzheimers Res Ther. 2019;11:1–9.